Enzalutamide Active in Low-, Intermediate-Risk Prostate Cancer
Significant reduction seen in risk of prostate cancer progression for enzalutamide plus AS versus active surveillance alone
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.